GSK to appeal Argentine fines on vaccine trial; AZ breaks ground on $230M Chinese factory;

@FiercePharma: The top 10 pharma layoffs of 2011. Report | Follow @FiercePharma

> GlaxoSmithKline ($GSK) plans to appeal Argentine fines over inadequate documentation and informed consent irregularities in a vaccine trial, the company said. News

> AstraZeneca ($AZN) started construction on a $230 million factory in Jiangsu, China, that's set to be the drugmaker's largest manufacturing facility when it's complete in 2013. Story

> Contract manufacturer Ben Venue extended the shutdown of its Bedford, Ohio, plant as it struggles to fix manufacturing problems identified by FDA. Article

> Stada said it had cut the size of its licensing deal with Grunenthal to cover product rights in Eastern Europe and the Middle East for $197 million, leaving Central European rights out of the arrangement. Report

> New Jersey's pharma industry shrank by 17% from 2009 to 2011, a trade group found, but the drug business remains a "primary economic driver" in the state. News

> Sinovac Biotech, a Chinese vaccines provider, said Chup Hung Mok resigned from its board; a replacement search has begun. Release

> Piper Jaffray analysts reiterated their "overweight" rating on Vertex Pharmaceuticals ($VRTX), after other investment firms upgraded the stock over the past few weeks. More

> A Teva Animal Health plant in Missouri that's been idling since FDA ordered it to clean up its act is expected to restart vaccine production this quarter. Report

Biotech News

@FierceBiotech: Countering skeptics, Alnylam claims pioneering first in RNAi cholesterol study. Article | Follow @FierceBiotech

@JohnCFierce: Biogen Idec strikes $299M deal for Isis antisense drug. Story | Follow @JohnCFierce

@RyanMFierce: Quintiles has formed a new digital unit, using websites to tap patients for trials. News | Follow @RyanMFierce

> Biotechs round up new venture cash for COPD, Alzheimer's programs. News

> Biogen Idec strikes $299M deal for Isis antisense drug. Article

> Countering skeptics, Alnylam claims pioneering first in RNAi cholesterol study. Piece

> After calling off Poniard merger, Allozyne "redistributing" staff. More

Medical Device News

> Corinthian raises $2M, sets sights on eye drug delivery device. Story

> Medtronic gets FDA OK for remote diabetes monitor. News

> Smith & Nephew to spin off biologics unit into JV. Article

> AirStrip scores regulatory win in EU. More

Drug Delivery News

> India researchers pursue nanoparticle rabies treatment. Report

> New year brings new delay for SkyePharma's Flutiform asthma inhaler. Article

> ThromboGenics gears up marketing plans for eyeball injection drug. Story

> FDA issues new guidelines for transmucosal delivery of pain drug. News

> Veloxis, Athena ink deal for pill combining 2 heart disease drugs. Item

> Alnylam, Medtronic RNAi drug-device combo wows with preclinical data. Report

Biomarker News

> Biomarker could quickly diagnose heart attack. Story

> Breast cancer gene triggers mesothelioma response. Report

> When it comes to weight loss, watch the biomarkers and not the scale. Article

> CSF biomarkers could differentiate types of dementia. News

> Brain imaging could serve as Huntington's disease biomarker. Report

> Alzheimer's disease imaging signature predicts cognitive. Item

And Finally... Patients who don't take their meds cost the U.S. healthcare system $290 billion in extra treatment, a study finds. More

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.